Cambridge Healthtech Institute’s 9th Annual
Preclinical Strategies, Models and Tools in Oncology
Translational Strategies, Novel Therapeutics and Tumor Models
September 17-18, 2020
The rise of cancer immunotherapy instigated unique preclinical and translational challenges. In addition to immuno-oncology advances, we are witnessing a new wave of targeted and novel therapies that enrich the arsenal of combination cancer therapies.
The demand for predictive and robust preclinical models and approaches to minimize translational failures in oncology and immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for early identification of predictive
biomarkers, for rational design of combination therapies, and for researching the cancer-immune cell interactions adds to the complexity of translational research in oncology and immuno-oncology. Cambridge Healthtech Institute’s 9th Annual
Preclinical Strategies, Models and Tools in Oncology conference is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Preliminary Agenda
SC6: In vitro and in vivo Modeling for Cancer Research - Detailed Agenda
*Separate registration required.
Exploring Novel Immunotherapy Combinations to Overcome Resistance to PD-1 Blockade
Russell Jenkins, MD, PhD, Assistant Professor, Medicine, Center for Cancer Research, Massachusetts General Hospital
In vivo Imaging Techniques for Model Characterization and Guiding Combination Strategies
Tapan Nayak, PhD, Director, Translational Imaging Biomarkers, Merck & Co., Inc.
TGFβ-Blockade Uncovers Stromal Plasticity in Tumors by Revealing the Existence of a Novel Subset of Interferon-Licensed Fibroblasts
Viviana Cremasco, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis
Development of a T-Cell Redirecting CD3 Bispecific Antibody for the Treatment of Gastrointestinal Tumors
Lindsay King, PhD, Associate Research Fellow, Biomedicines Design, Pfizer
Friends & Enemies: Spatial Mapping of Regulatory T Lymphocytes in Inflammatory Microenvironments
Shawn O’Neill, DVM, PhD, Senior Director, Global Pathology & Investigative Toxicology, Global Microscopic Imaging Lead, Drug Safety Research & Development, Pfizer Worldwide Research & Development
Targeting Tumor-Promoting Inflammation via the Inflammasome Pathway – Lessons Learned
Pushpa Jayaraman, PhD, Senior Investigator I, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research
Targeting Immune Checkpoint TIM-3 for Cancer Immunotherapy
Xiaomo Jiang, PhD, Principal Scientist II, Immuno-Oncology, Novartis Institutes for BioMedical Research
Novel Fully Synthetic Bicyclic Peptides as Tumor Targeted Immune Cell Modulators
Sailaja Battula, PhD, Associate Director, Immuno-Oncology, Bicycle Therapeutics
‘Smart’ Release Therapeutics Target Multi-Drug Resistance in Solid Cancers
Aaron Goldman, PhD, Faculty and Principal Investigator, Goldman Laboratory Drug Resistance Group, Harvard Medical School
Is There a Key Node in the TME to Tip the Balance?
Zhao Chen, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, Inc.
Transplanted Syngeneic Metastasis Models for Preclinical Applications
Viswanathan Muthusamy, PhD, Research Scientist; Executive Director, Center for Precision Cancer Modeling, Yale School of Medicine
Using Humanized Mouse Models to Evaluate IO Therapeutics
Virna Cortez-Retamozo, PhD, Lab Head, Senior Principal Scientist, Oncology-Pharmacology, Sanofi
For more details on the conference, please contact:
Marina Filshtinsky, MD
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5496
Email: mfilshtinsky@healthtech.com
For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com